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Abstract
Angiogenesis is essential for tumor growth and progression. It has been demonstrated that tumor growth beyond
a size 1 to 2 mm3 requires the induction of new vessels. Angiogenesis is regulated by several endogenous stim-
ulators and inhibitors of endothelial cell migration, proliferation and tube formation. Under physiological con-
ditions these mediators of endothelial cell growth are in balance and vessel growth is limited. In fact, within the
angiogenic balance endothelial cell turnover is sufficient to maintain a functional vascular wall but does not
allow vessel growth. Tumor growth an progression has successfully been correlated to the serum concentration
of angiogenic mediators. Furthermore, the vascular density of tumor tissues could be correlated to the clinical
course of the disease in several tumor entities. Within the last years several new mediators of endothelial cell
growth have been isolated e.g. angiopoietin 1, angiopoietin 2, midkine, pleiotropin, leptin and maspin. In this
review we discuss the mechanisms leading to tumor angiogenesis and describe some of the newer mediators of
endothelial cell stimulation and inhibition.
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Introduction
Angiogenesis, the formation of new blood vessels
from preexisting capillaries, is essential for tumor
growth and progression. Normal tissues are in an
angiogenic balance, meaning that the endothelial
cells divide to maintain a functional vascular wall,
but the proliferation rate does not allow vascular
growth. However, normal angiogenesis is tightly
controlled and only activated for a defined period of
time. In endometrium normal angiogenesis is acti-
vated during the proliferative phase while in the
secretory phase angiogenesis is inhibited. The
angiogenic balance is maintained by several
endogenous stimulators and inhibitors of endothe-
lial cell growth. In tumor tissue this angiogenic bal-
ance is shifted towards the stimulation of vascular
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Mini  reviewgrowth. In conclusion tumor angiogenesis or patho-
logical angiogenesis can be understood as a disrup-
tion of normal control mechanisms of endothelial
cell growth. 
Several stimulators and inhibitors of angiogene-
sis have been identified within the last decades (see
Table 1 and 2). The expressions of basic-fibroblast
growth factor (b-FGF or FGF-2) and vascular
endothelial growth factor (VEGF) have been inves-
tigated in numerous different tumors and have suc-
cessfully been correlated to the clinical course of
the disease. In this review we will focus on the
induction of vessel growth by tumor tissue and will
describe some of the newer stimulators and
inhibitors of angiogenesis which have not that
extensively been investigated in cancers. The fac-
tors that are discussed in this review are angiopoi-
etin-1 (Ang-1), angiopoietin-2 (Ang-2), leptin, mid-
kine, pleiotropin and maspin. (Fig. 1)
Tumor Angiogenesis
For more than 100 years, tumors had been observed
to be more vascularized than normal tissues [1].
However, vasodilatation of host vessels were
thought to be the reason for tumor hyperemia [2]. In
1939 a paper by Ide et al. [3] hypothesized for the
first time that tumor hyperemia could be related to
new blood vessel growth instead of vasodilatation.
Today it is widely accepted that vessel growth,
induced by tumor cells, leads to hypervasculariza-
tion of tumor tissue (tumor growth is angiogenic)
[4]. Furthermore, in 1971 Judah Folkman proposed
that tumor growth depends on the induction of ves-
sel growth (tumor growth is angiogenesis depend-
ent) [5]. This would imply that in principle malig-
nant tumors could be treated by a therapy directed
towards the tumor vasculature. Today antiangio-
genic agents are in numerous phase I to III clinical
trials to test their antitumor activity in humans [6].
Under physiological conditions the vasculature
is quiescent in the normal adult. Only 0.01% of
endothelial cells in a normal adult vessel are in the
cell division cycle at any given time [7]. However,
in response to an appropriate angiogenic stimulus,
the endothelial cells can become activated to grow
new vessels. The induction of vessel growth is a
complex process, where the basement membrane of
the vessel is degraded, the underlying endothelial
cells migrate into the surrounding stroma and pro-
liferate at the tip of the migrating column [8]. The
time point where angiogenesis is induced in a
malignant tumor is named the “angiogenic switch”.
Until this stage of tumor progression is reached a
tumor is avascular, small (0.5 to 2.0 mm in diame-
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Acidic fibroblast growth factor (FGF-1)
Angiogenin
Angiopoietins
Basic fibroblast growth factor (FGF-2)
Granulocyte colony-stimulating factor
Hepatocyte growth factor
Insulin like growth factor
Interleukin-8
Leptin
Midkine
Platelet-derived endothelial cell growth factor
Placental growth factor
Pleiotropin
Proliferin
Transforming growth factor alpha
Transforming growth factor beta
Tumor necrosis factor alpha
Vascular endothelial growth factors
Table 1 Endogenous stimulators of angiogenesis.
Antithrombin
Angiostatin
Endostatin
Interferon alpha
Interleukin-12
Maspin
Matrix metalloproteinases
Plasminogen activator inhibitor 1
Prolactin
Thrombospondin
Troponin I
Table 2 Endogenous inhibitors of angiogenesis.ter) and the proliferation and apoptosis of tumor
cells is in balance [9]. After going through the
angiogenic switch the tumor is vascularized, grows
to clinically recognizable size and the balance of
tumor cell apoptosis and proliferation are shifted
towards proliferation. 
The process of metastasis is also angiogenesis
dependent. For a tumor cell to metastasize success-
fully, it needs access to a vessel, survive within the
circulation, exit from the vessel in the target organ,
seed in the organ stroma and induce angiogenesis
[10]. Therefore, angiogenesis is essential at the
beginning and at the end of the metastatic cascade. 
While tumors are hypervascularized and tumor
growth and metastasis are angiogenesis dependent,
the question has been raised, if the degree of hyper-
vascularization can be correlated to the prognosis of
the disease. Weidner and colleagues in 1991 [11]
found that the microvascular density of the primary
tumor was a highly significant prognostic marker
for human breast cancer [12]. Since then, many
studies have found the vascular density to be a
prognostic marker for numerous different tumor
entities (e.g. prostate cancer, non-small cell lung
cancer, colorectal cancer and malignant melanoma)
[12-15]. 
A considerable amount of research has been
devoted to the question how tumors induce angio-
genesis. The observation that angiogenic tumors
could be implanted into an avascular region such as
the cornea and than activate the sprouting of new
capillaries from distant vessels (e.g. limbus ves-
sels), suggested that tumors release diffusible stim-
ulators of angiogenesis [16]. Today it is widely
accepted that tumors (that went through the angio-
genic switch) stimulate angiogenesis by the release
of angiogenesis stimulators (e.g. basic-fibroblast
growth factor and vascular endothelial growth fac-
tor). On the other hand, it has been demonstrated
that tumors also induce angiogenesis through the
down regulation or inhibition of endogenous angio-
genesis inhibitors (e.g. thrombospondin-1) [17]. In
many studies the serum or tumor levels of angio-
genesis stimulators and/or angiogenesis inhibitors
could also be identified as a prognostic marker for
different tumor entities [18-20]. 
Angiopoietin 1 and 
Angiopoietin 2 
Two families of receptors have been identified
whose expression in the human body is mainly
restricted to endothelial cells. One family contains
the vascular endothelial growth factor (VEGF)
receptors (Flt-1, Flt-4 and Flk-1/KDR) which are
important during vascular development [21, 22].
The other family contains the tyrosine receptor
type ties (Tie1 and Tie2/Tek) and has been found to
be essential for vascular formation [23, 24]. Ang-1
has been isolated in 1996, for its ability to bind and
activate the Tie2 receptor [25]. Ang-1 is a 70 kDa
glycoprotein that during early embryonic life is
most prominently expressed in the heart and later
during development becomes more widely distrib-
uted (but always in vessels) [25]. Ang-1 although
activating the Tie2 receptor did not induce
endothelial cell proliferation or tube formation in
vitro. Therefore, it was suggested that Ang-1, in
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Fig. 1 Effect of the angiogenesis mediators on endothelial and tumor cells. "+" indicates stimulation
and "-" indicates inhibition.contrast to VEGF that acts early in blood vessel
development, plays a role later during vessel
remodeling, maturation and stabilization [25].
However, in an assay where endothelial cells were
cultured on beads and embedded in fibrin gels,
Ang-1 induced the formation of capillary sprouts
[26]. In this assay suboptimal concentrations of
VEGF and Ang-1 acted synergistically to induce
sprout formation [26]. In contrast to VEGF which
was also named VPF (vascular permeability factor)
and induces vascular leakage, Ang-1 acts as an
antipermeability factor on the vascular wall [27,
28]. Exposure to low oxygen led to a rise of Tie2
protein expression in human endothelial cells [29].
It is very well known that in tumor tissue the oxy-
gen concentration is much lower than in normal tis-
sue, therefore the overexpression of Tie2 in hypox-
ic tumor endothelium in combination with high
Ang-1 could be a mechanism for stimulation of
angiogenesis in malignant tumors [29]. Consistent
with this theory Takahama and colleagues found an
elevated and correlating expression of Tie2, Ang-1,
VEGF and CD-31 in 32 non-small cell lung can-
cers compared to normal lung tissue. The authors
concluded that Ang-1 and VEGF are important
angiogenic factors in human non-small cell lung
cancer [30]. 
In 1997 an Ang-1 relative, named Ang-2, was
identified and shown to be a naturally occurring
antagonist of Ang-1 and Tie2 [31]. Ang-2, like
Ang-1, binds to the Tie2 receptor but does not
send a downstream signal [31]. Therefore, the
receptor is occupied and not available for activa-
tion through Ang-1. These data suggest that Ang-
2 counteracts blood vessel maturation and stabi-
lization mediated by Ang-1. Ang-2 is mainly
expressed in microvascular endothelial cells at
sits of blood vessel regression and regeneration. It
has been shown that endothelial cell levels of
Ang-2 were increased by VEGF, b-FGF and
hypoxia, whereas Ang-1 decreased Ang-2 expres-
sion [32]. This observations led to the suggestion
that the angiogenic effect of these factors, at least
in part, is achieved by the regulation of an
autocrine loop of Ang-2 in endothelial cells [32].
Prevailing view of the initiation of tumor angio-
genesis is that the tumor first exists as an avascu-
lar tumor cell mass that goes through the angio-
genic switch and than attracts vessels by the
secretion of angiogenesis stimulators. Two papers
by Holash and coworkers suggested a different
mechanism for the initiation of tumor angiogene-
sis [33, 34]. The authors found that malignant
cells rapidly coopted host vessels to form an ini-
tially well-vascularized tumor mass. The coopted
vessel did not undergo angiogenesis but regressed
via a mechanism that involved disruption of
endothelial cell/smooth muscle cell interactions
and endothelial apoptosis. This vessel regression
resulted in secondarily avascular tumors and mas-
sive tumor cell loss resulting in a necrotic center
of the tumor. Ultimately the tumor is rescued by
robust angiogenesis that is initiated at the margin
of the tumor and that supports rapid tumor
growth. The induction of Ang-2 in the coopted
host vessel correlates with vessel regression and
precedes the induction of VEGF expression in the
adjacent tumor cells that leads to the robust
angiogenic response. The authors concluded that
the previously underappreciated balance between
vascular regression and growth might be impor-
tant for the induction of tumor angiogenesis.
Consistent with this observation Wong and
coworkers [35] found a significant up-regulation
of VEGF in non-small cell lung tumor cells that
could be correlated to the number of Ang-2
expressing vessels in the tumor. In contrast, nor-
mal lung tissue expressed high and correlating
levels of Ang-1 and Tie2 which were significant-
ly reduced in the lung tumors [35]. In 23 samples
of hepatocellular carcinomas (HCC) and adjacent
normal liver tissue Tanaka et al. investigated the
expression of Ang-1 and Ang-2 [36]. They found
that Ang-1 was equally expressed in HCC and
normal liver tissue. On the other side, Ang-2 was
highly expressed in 10 of 12 hypervascular HCC,
but only in 2 of 11 hypovascular HCC, suggesting
a role for Ang-2 in the development of hypervas-
cularized HCC. Yoshida and colleagues found
that colorectal cancers overexpressed Ang-2 (and
thrombospondin 2) when compared to normal
mucosa [37]. Overexpression of human epidermal
growth factor receptor 2 (HER2) is a marker for
aggressiveness in breast cancer. Carter and Ward
provided evidences that the expression of Ang-2
in breast cancer might be regulated by HER2 [38].
Recently alternative splice variants of Ang-1 and
Ang-2 have been identified [39, 40]. The expres-
sion and biological relevance of these splice vari-
ants in tumor angiogenesis has to be investigated. 
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Obesity is characterized by an excess of fat mass
as a consequence of adipocyte hypertrophy and
hyperplasia. In 1995, leptin, the product of the ob
gene was identified [41]. Leptin is a cytokine,
generated and secreted by adipocytes, that regu-
lates many physiological processes, for example
body weight, energy homeostasis, ovarian devel-
opment, steroidogenesis and serves as a permis-
sive regulator of sexual maturation [42, 43].
Because adipocytes possess angiogenic activity
[44] and the growth of adipose tissue requires the
formation of new blood vessels, it has been sug-
gested that leptin might stimulate endothelial cell
proliferation and angiogenesis [45]. It could be
demonstrated that endothelial cells in vitro
express at least two forms of leptin receptors (Ob-
Ra amd Ob-Rb) and that these could be activated
by the treatment of cultured endothelial cells with
leptin (10 ng/mL) [45, 46]. Furthermore, it has
been shown that leptin promotes endothelial cell
survival and proliferation in vitro [45, 46] and
stimulates angiogenesis in vivo when using the
chicken chorioallantoic membrane assay (CAM)
[45, 46]. Uckaya and colleagues found that
patients suffering from diabetic retinopathy (an
angiogenic disease) had higher plasma leptin lev-
els the more advanced the retinopathy was [47].
Leptin as an angiogenesis factor is almost not
investigated in tumor angiogenesis, however,
Bertolini and coworkers found no differences for
circulating leptin levels in patients with non-
Hodgkin’s lymphoma that had complete remis-
sion or were in progression [48]. It is interesting
that cancer patients with advanced diseases often
suffer from extensive weight loss (tumor cachex-
ia). In breast cancer patients elevated plasma lev-
els and adipose tissue expression of leptin have
been found [49], while in other cancers e.g. col-
orectal and lung cancer this correlation could not
be seen [49, 50]. Especially no correlation for
tumor cachexia and elevated leptin levels have
been found so far. However, the interaction of
leptin expression, tumor growth and cachexia are
not understood today, but one has to keep in mind
that stimulation and inhibition of angiogenesis is
a local process and is not necessarily mirrored by
elevated serum levels of angiogenic mediators.
Midkine and Pleiotropin
Midkine (MK) and pleiotropin (PTN) are heparin-
binding cytokines that are involved in neurogenesis,
cell migration and mesoderm-epithelial interactions
[51]. In 1997 Choudhuri et al. investigated the role of
these two growth factors in tumorigenesis [52].
Employing different in vitro and in vivo assays they
found that in vitro tumor cell growth is not affected by
these growth factors. However, in vivo tumor cell
growth was stimulated and this growth advantage cor-
related to an increase of the vascular density of the
tumors [52]. In the same study the angiogenic activity
of MK and PTN was confirmed in an rabbit corneal
assay. In 47 primary bladder tumors and 7 normal
bladder samples MK expression was identified in 98%
of tumor samples and 70% of normal bladder tissues.
However, median MK expression was 4-fold higher in
tumors than in normal bladders [53]. Furthermore,
overexpression of MK predicted a poor outcome in
patients with invasive bladder cancer [53]. In thyroid
papillary carcinomas the expression of MK has been
shown to relate to the invasion of these carcinomas
[54]. Two other studies have demonstrated an overex-
pression of MK in hepatocellular carcinomas and
Sternberg Reed cells of Hodgkin’s disease [55, 56].
Ikematsu et al. investigated serum MK levels in 135
normal individuums and 150 patients with different
types of cancer [57]. In this study the serum MK level
for normal individuums has been 0.154 + 0.076
ng/mL. Using a cut-off value of 0.5 ng/mL, 87% of
cancer patients showed elevated MK serum levels.
Because serum MK levels did not correlate to serum
C-reaktive protein levels, a marker for inflammation,
the authors stated that MK could be used as a general
tumor marker [57]. The expression of MK and PTN
was examined in normal and malignant human breast
tissue. The majority of both malignant and normal
breast tissues expressed PTN, whereas MK was fre-
quently expressed in the malignant breast tissue but in
only one of the normal specimens [58]. Studies corre-
lating MK and PTN expression to angiogenic charac-
teristics like vascular density are missing.
Maspin
Maspin, a tumor suppressing serpin (serin protease
inhibitors), has been isolated from mammary
266epithelial cells [59]. The maspin protein is
expressed in normal mammary epithelial cells but
not in most mammary carcinoma cell lines [59].
The loss of maspin expression occurred most fre-
quently in advanced cancers [59]. Rat maspin
mRNA was detected in rat mammary gland, vagina,
urinary bladder, thymus, small intestine, skin, ven-
tral prostate, seminal vesicles, and thyroid but not in
heart, lung, liver, brain and kidney [60]. Maspin has
been shown to inhibit cell motility, tumor invasion,
and development of metastasis [61, 62, 63]. In a
recent publication by Zhang and colleagues demon-
strated that maspin is a potent inhibitor of angiogene-
sis [64]. In vitro, maspin inhibited b-FGF and VEGF
stimulated endothelial cell (migration towards b-FGF
and VEGF), and reduced endothelial cell proliferation
and tube formation. In vivo, maspin blocked neovas-
cularization in the rat cornea pocket model [64]. In 44
cases of human oral squamous cell carcinomas the
expression of maspin has been correlated to patient
survival. Sixtysix % of cases expressed low to inter-
mediate levels of maspin and 34% of cases expressed
high levels of maspin. High maspin levels were asso-
ciated with the absence of lymph node metastasis and,
more importantly, were significantly correlated with a
better overall survival [65]. As mentioned above,
maspin belongs to the superfamily of serpins (serine
protease inhibitor). Recently two  other serpins,
antithrombin (AT-III) and plasminogen activator
inhibitor I (PAI-I), have been demonstrated to exert
antiangiogenic activity [66, 67]. 
Conclusion
In this review we described some of the newer
molecular mediators of angiogenesis. Most of the
factors described here, have originally been isolated
for other biological functions, but later have been
demonstrated to be angiogenic or antiangiogenic.
While other angiogenesis mediators, e.g. b-FGF and
VEGF, are extensively characterized in tumor angio-
genesis, these factors are not that well investigated.
As described above, interactions for angiopoietins
and VEGF in tumor angiogenesis have been found,
but in general the interactions and functional mecha-
nisms of angiogenesis mediators are not that well
understood. Furthermore, the therapeutic potential of
the regulation of angiogenesis in malignant and other
diseases is of utmost importance. The dependence of
tumor growth and progression from the induction of
vessel growth builts a potential new strategy in the
fight against cancer. To design effective and save
antiangiogenic regimes against cancer investigation
of the mechanisms of tumor angiogenesis and the
interactions of its mediators are essential. 
References
1. Warran B.A., The vascular morphology of tumors. In:
Peterson H.I. editor, Tumor blood circulation:
Angiogenesis, vascular morphology and blood flow of
experimental human tumors. CRC Press 1979, Miami,
FL pp. 1-47
2. Coman D.R., Sheldon W.F., The significance of hyper-
emia around tumor implants, Am. J. Pathol., 22:821, 1946.
3. Ide A.G., Baker N.H., Warren S.L., Vascularization of
the Brown-Peatce rabbit epithelioma transplant as seen
in the transparent ear chamber, Am. J. Roentgenol.,
42:891, 1939
4. Hanahan D., Weinberg R.A., The hallmarks of cancer,
Cell, 100:57, 2000
5. Folkman J., Tumor angiogenesis: therapeutic implica-
tions, N. Engl. J. Med., 285:1182, 1971
6. Webpage of the National Cancer Institute,
http://www.nci.nih.gov
7. Hobson B., Denekamp J., Endothelial proliferation in
tumors and normal tissues: continouus labeling studies, Br.
J. Cancer, 49:405, 1984
8. Auerbach W., Auerbach R., Angiogenesis inhibition: a
review, Pharmacol. Ther., 63:265, 1994
9. Hanahan D., Folkman J., Patterns and emerging mecha-
nisms of the angiogenic switch during tumorigenesis, Cell,
86:353, 1996
10. Weinstat-Saslow D., Steeg P.S., Angiogenesis and colo-
nization in the tumor metastatic process: basic and applied
advances, FASEB J., 8:401, 1994
11. Weidner N., Semple J.P., Welch W.R., Folkman J.,
Tumor angiogenesis correlates with metastasis in invasive
breast carcinoma, N. Engl. J. Med., 324:1, 1991
12. Weidner N., Carroll P.R., Flax J., Blumenfeld W.,
Folkman J., Tumor angiogenesis correlates with metasta-
sis in invasive prostate carcinoma, Am. J. Pathol.,
143:401, 1993
13. Fontanini G., Lucchi M., Vignati S., Mussi A.,
Ciardiello F., DeLaurentiis M., De Placido S., Basolo
F., Angeletti C.A., Bevilacqua G., Angiogenesis as a
prognostic indicator of survival in non-small cell lung
carcinoma: a prospective study, J. Natl. Cancer Inst.,
89:881, 1997
14. Lindmark G., Gerdin B, Sundberg C, Pahlman L.,
Bergstrom R., Glimelius B., Prognostic significance of
microvascular count in colorectal cancer, J. Clin. Oncol.,
14:461, 1996
267
J.Cell.Mol.Med. Vol 4, No 4, 200015. Srivastava A., Laidler P., Davies R.P., Horfan K., The
prognostic significance of tumor vascularity in interme-
diate-thickness (0.76-4.0 mm) skin melanoma. A quanti-
tative histologic study, Am. J. Pathol., 133:419, 1988
16. Gimbrone M.A., Cotran R., Leapman S., Folkman
J.,  Tumor growth and neovascularization: an experi-
mental model using rabbit cornea, J. Natl. Cancer Inst.,
52:413, 1974
17. Campbell S.C., Volpert O.V., Ivanovich M., Bouck N.P.,
Molecular mediators of angiogenesis in bladder cancer,
Cancer Res., 56:1298, 1998
18. Loncaster J.A., Cooper R.A., Logue J.P., Davidson S.E.,
Hunter R.D., West C.M., Vascular endothelial growth fac-
tor (VEGF) expression is a prognostic factor for radiother-
apy outcome in advanced carcinoma of the cervix, Br. J.
Cancer, 83:620, 2000
19. Shen G.H., Ghazizadeh M., Kawanami O., Shimizu H.,
Jin E., Araki T., Sugisaki Y., Prognostic significance of
vascular endothelial growth factor expression in human
ovarian carcinoma, Br. J. Cancer, 83: 196, 2000
20. Mineta H., Miura K., Ogino T., Takebayashi S.,
Misawa K., Ueda Y., Suzuki I., Dictor M., Borg A.,
Wennerberg J., Prognostic value of vascular endothelial
growth factor (VEGF) in head and neck squamous cell
carcinoma, Br. J. Cancer, 83:775, 2000
21. Lee J., Gray A., Yuan J., Luoh S.M., Avraham H., Wood
W.I.., Vascular endothelial growth factor-related protein: a
ligand and specific activator of the tyrosine kinase receptor
Flt4, Proc. Natl. Acad. Sci., 93:1988, 1996
22. Borg J.P., deLapeyriere O., Noguchi T., Rottapel R.,
Dubreuil P., Birnbaum D., Biochemical characterization
of two isoforms of FLT4, a VEGF receptor-related tyrosine
kinase, Oncogene, 10:973, 1995
23. Dumont D.J., Yamaguchi T.P., Conlon R.A., Rossant
J., Breitman M.L., Tek, novel tyrosine kinase gene
located on mouse chromosome , is expressed in endothe-
lial cells and their presumptive precursor, Oncogene,
7:1471, 1992
24. Puri M.C., Rossant J., Alitalo K., Bernstein A.,
Partanen J., The receptor tyrosine kinase TIE is required
for intergity and survival of vascular endothelial cells,
EMBO J., 14:5884, 1995
25. Davis S., Aldrich T.H., Jones P.F., Acheson A., Compton
D.L., Jain V., Ryan T.E., Bruno J., Radziejewski C.,
Maisonpierre P.C., Yancopoulos G.D., Isolation of
angiopoietin-1, a ligand for the TIE2 receptor, by secretion-
trap expression cloning [see comments], Cell, 87:1161, 1996
26. Koblizek T.I., Weiss C., Yancopoulos G.D., Deutsch U.,
Risau W., Angiopoietin-1 induces sprouting angiogenesis
in vitro, Curr. Biol., 8:529, 1998
27. Thurston G., Rudge J.S., Ioffe E., Zhou H., Ross L.,
Croll S.D., Glazer N., Holash J., McDonald D.M.,
Yancopoulos G.D., Angiopoietin-1 protects the adult vas-
culature against plasma leakage, Nat. Med., 6:460, 2000
28. Gamble J.R., Drew J., Trezise L., Underwood A.,
Parsons M., Kasminkas L., Rudge J., Yancopoulos G.,
Vadas M.A., Angiopoietin-1 is an antipermeability and
anti-inflammatory agent In vitro and targets cell junctions
[In Process Citation], Circ. Res., 87:603, 2000
29. Willam C., Koehne P., Jurgensen J.S., Grafe M.,
Wagner K.D., Bachmann S., Frei U., Eckardt K.U.,
Tie2 receptor expression is stimulated by hypoxia and
proinflammatory cytokines in human endothelial cells,
Circ. Res., 87:370, 2000
30. Takahama M., Tsutsumi M., Tsujiuchi T., Nezu K.,
Kushibe K., Taniguchi S., Kotake Y., Konishi Y.,
Enhanced expression of Tie2, its ligand angiopoietin-1, vas-
cular endothelial growth factor, and CD31 in human non-
small cell lung carcinomas, Clin. Cancer Res., 5:2506, 1999
31. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S.,
Wiegand S.J., Radziejewski C., Compton D., McClain
J., Aldrich T.H., Papadopoulos N., Daly T.J., Davis S.,
Sato T.N., Yancopoulos G.D., Angiopoietin-2, a natural
antagonist for Tie2 that disrupts in vivo angiogenesis [see
comments], Science, 277:55, 1997
32. Mandriota, S.J., Pepper M.S., Regulation of angiopoi-
etin-2 mRNA levels in bovine microvascular endothelial
cells by cytokines and hypoxia, Circ. Res., 83:852, 1998
33. Holash J., Wiegand S.J., Yancopoulos G.D., New model
of tumor angiogenesis: dynamic balance between vessel
regression and growth mediated by angiopoietins and
VEGF, Oncogene, 18:5356, 1999
34. Holash J., Maisonpierre P.C., Compton D., Boland P.,
Alexander C.R., Zagzag D., Yancopoulos G.D., Wiegand
S.J., Vessel cooption, regression, and growth in tumors medi-
ated by angiopoietins and VEGF, Science, 284:1994, 1999
35. Wong M.P., Chan S.Y., Fu K.H., Leung S.Y., Cheung N.,
Yuen S.T., Chung L.P., The angiopoietins, tie2 and vascu-
lar endothelial growth factor are differentially expressed in
the transformation of normal lung to non-small cell lung
carcinomas, Lung Cancer, 29:11, 2000
36. Tanaka S., Mori M., Sakamoto Y., Makuuchi M.,
Sugimachi K., Wands J.R., Biologic significance of
angiopoietin-2 expression in human hepatocellular carcino-
ma, J. Clin. Invest., 103:341, 1999
37. Yoshida Y., Oshika Y., Fukushima Y., Tokunaga T.,
Hatanaka H., Kijima H., Yamazaki H., Ueyama Y.,
Tamaoki N., Miura S., Nakamura M., Expression of angio-
static factors in colorectal cancer,Int. J. Oncol., 15:1221, 1999
38. Carter W.B., Ward M.D., HER2 regulatory control of
angiopoietin-2 in breast cancer, Surgery, 128:153, 2000.
39. Kim I., Kim J.H., Ryu Y.S., Jung S.H., Nah J.J., Koh
G.Y., Characterization and expression of a novel alterna-
tively spliced human angiopoietin-2, J. Biol. Chem.,
275:18550, 2000
40. Huang Y.Q., Li J.J., Karpatkin S., Identification of a
family of alternatively spliced mRNA species of angiopoi-
etin-1, Blood, 95:1993, 2000
41. Pelleymounter M., Cullen M., Baker M., Hecht R.,
Winters D., Boone T., Collins F., Effects of the obese gene
product on body weight regulation in ob/ob mice, Science,
269:540, 1995
42. Henson M.C., Castracane V.D., Leptin in pregnancy [In
Process Citation], Biol. Reprod., 63:1219, 2000
43. Marti A., Berraondo B., Martinez J.A., Leptin: physio-
logical actions, J. Physiol. Biochem., 55:43, 1999.
44. Green H., Kehinde O., Formation of normally differenti-
ated subcutaneous fat pads by an established preadipose
cell line, J. Cell Physiol., 101:169, 1979
45. Bouloumie A., Drexler H.C., Lafontan M., Busse R.,
Leptin, the product of Ob gene, promotes angiogenesis,
Circ. Res., 83:1059, 1998
26846. Sierra-Honigmann M.R., Nath A.K., Murakami C.,
Garcia-Cardena G., Papapetropoulos A., Sessa W.C.,
Madge L.A., Schechner J.S., Schwabb M.B., Polverini
P.J., Flores-Riveros J.R., Biological action of leptin as an
angiogenic factor [see comments], Science, 281:1683, 1998
47. Uckaya G., Ozata M., Bayraktar Z., Erten V., Bingol N.,
Ozdemir I.C., Is leptin associated with diabetic retinopa-
thy?, Diabetes Care, 23:371, 2000
48. Bertolini F., Paolucci M., Peccatori F., Cinieri S., Agazzi
A., Ferrucci P.F., Cocorocchio E., Goldhirsch A.,
Martinelli G., Angiogenic growth factors and endostatin in
non-Hodgkin’s lymphoma [see comments], Br. J.
Haematol., 106:504, 1999
49. Tessitore L., Vizio B., Jenkins O., De Stefano I., Ritossa
C., Argiles J.M., Benedetto C., Mussa A., Leptin expres-
sion in colorectal and breast cancer patients, Int. J. Mol.
Med. 5:421, 2000
50. Simons J.P., Schols A.M., Campfield L.A., Wouters E.F.,
Saris W.H., Plasma concentration of total leptin and
human lung-cancer associated cachexia, Clin. Sci. (Colch.)
93:273, 1997
51. Zhang N., Deuel T.F., Pleiotrophin and midkine, a family
of mitogenic and angiogenic heparin-binding growth and
differentiation factors, Curr. Opin. Hematol., 6:44, 1999
52. Choudhuri R., Zhang H.T., Donnini S., Ziche M.,
Bicknell R., An angiogenic role for the neurokines mid-
kine and pleiotrophin in tumorigenesis, Cancer Res.,
57:1814, 1997
53. O’Brien T., Cranston D., Fuggle S., Bicknell R., Harris
AL., The angiogenic factor midkine is expressed in bladder
cancer, and overexpression correlates with a poor outcome in
patients with invasive cancers, Cancer Res., 56:2515, 1996
54. Kato M., Maeta H., Kato S., Shinozawa T., Terada T.,
Immunohistochemical and in situ hybridization analyses of
midkine expression in thyroid papillary carcinoma [In
Process Citation], Mod. Pathol., 13:1060, 2000
55. Kato M., Shinozawa T., Kato S., Awaya A., Terada T.,
Increased midkine expression in hepatocellular carcinoma,
Arch. Pathol. Lab. Med., 124:848, 2000
56. Kato H., Watanabe K., Murari M., Isogai C., Kinoshita
T., Nagai H., Ohashi H., Nagasaka T., Kadomatsu K.,
Muramatsu H., Muramatsu T., Saito H, Mori N.,
Murate T., Midkine expression in Reed-Sternberg cells of
Hodgkin’s disease, Leuk. Lymphoma, 37:415, 2000
57. Ikematsu S., Yano A., Aridome K., Kikuchi M., Kumai
H., Nagano H., Okamoto K., Oda M., Sakuma S., Aikou
T., Muramatsu H., Kadomatsu K., Muramatsu T.,
Serum midkine levels are increased in patients with various
types of carcinomas, Br. J. Cancer, 83:701, 2000
58. Garver R.I. Jr., Radford D.M., Donis-Keller H., Wick
M.R., Milner P.G., Midkine and pleiotrophin expression in
normal and malignant breast tissue, Cancer, 74:1584, 1994
59. Zou Z., Anisowicz A., Hendrix M.J., ThorA., Neveu M.,
Sheng S., Rafidi K., Seftor E., Sager R., Maspin, a serpin
with tumor-suppressing activity in human mammary
epithelial cells [see comments], Science, 263:526, 1994
60. Umekita Y., Hiipakka R.A., Liao S., Rat and human
maspins: structures, metastatic suppressor activity and muta-
tion in prostate cancer cells, Cancer Lett., 113:87, 1997
61. Sager R., Sheng S., Pemberton P., Hendrix M.J.,
Maspin. A tumor suppressing serpin, Adv. Exp. Med. Biol.,
425:77, 1997
62. Sheng S., Carey J., Seftor E.A., Dias L., Hendrix M.J.,
Sager R., Maspin acts at the cell membrane to inhibit inva-
sion and motility of mammary and prostatic cancer cells,
Proc. Natl. Acad. Sci. U S A, 93:11669, 1996
63. Zhang M., Sheng S., Maass N., Sager R., mMaspin: the
mouse homolog of a human tumor suppressor gene
inhibits mammary tumor invasion and motility, Mol. Med.
3:49, 1997
64. Zhang M., Volpert O., Shi Y.H., Bouck N., Maspin is an
angiogenesis inhibitor, Nat. Med. 6:196, 2000
65. Xia W., Lau Y.K., Hu M.C., Li L., Johnston D.A.,
Sheng S., El-Naggar A., Hung MC., High tumoral
maspin expression is associated with improved survival of
patients with oral squamous cell carcinoma, Oncogene,
19:2398, 2000
66. Stefansson S., Petitclerc E., Wong M.K., McMahon
G.A., Brooks P.C., Lawrence D.A., Inhibition of angio-
genesis  in vivo by plasminogen activator inhibitor-1, J.
Biol. Chem., in press
67. O’Reilly M.S., Pirie-Shepherd S., Lane W.S., Folkman
J., Antiangiogenic activity of the cleaved conformation of
the serpin antithrombin, Science, 285:1926, 1999
269
J.Cell.Mol.Med. Vol 4, No 4, 2000